Larry D. Cripe

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

Jonathan W. Friedberg, Jeff P. Sharman, John Sweetenham et al. · Blood · 2009 · 734 citations · Full text

BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein

Ann Marie Pendergast, Lawrence A. Quilliam, Larry D. Cripe et al. · Cell · 1993 · 656 citations

Signal Transduction, Signaling Pathway, Oncogenic Agent +9

Treatment With Ibritumomab Tiuxetan Radioimmunotherapy in Patients With Rituximab-Refractory Follicular Non-Hodgkin’s Lymphoma

Thomas E. Witzig, Ian W. Flinn, Leo I. Gordon et al. · Journal of Clinical Oncology · 2002 · 649 citations

Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

Mark J. Levis, Farhad Ravandi, Eunice S. Wang et al. · Blood · 2011 · 395 citations · Full text

Association of the Protein Kinases c-Bcr and Bcr-Abl with Proteins of the 14-3-3 Family

Gary W. Reuther, Haian Fu, Larry D. Cripe et al. · Science · 1994 · 230 citations